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ABSTRACT
Rationale Clinical trial design in interstitial lung
diseases (ILDs) has been hampered by lack of consensus
on appropriate outcome measures for reliably assessing
treatment response. In the setting of connective tissue
diseases (CTDs), some measures of ILD disease activity
and severity may be confounded by non-pulmonary
comorbidities.
Methods The Connective Tissue Disease associated
Interstitial Lung Disease (CTD-ILD) working group of
Outcome Measures in Rheumatology—a non-proﬁt
international organisation dedicated to consensus
methodology in identiﬁcation of outcome measures—
conducted a series of investigations which included a
Delphi process including >248 ILD medical experts as
well as patient focus groups culminating in a nominal
group panel of ILD experts and patients. The goal was
to deﬁne and develop a consensus on the status of
outcome measure candidates for use in randomised
controlled trials in CTD-ILD and idiopathic pulmonary
ﬁbrosis (IPF).
Results A core set comprising speciﬁc measures in the
domains of lung physiology, lung imaging, survival,
dyspnoea, cough and health-related quality of life is
proposed as appropriate for consideration for use in a
hypothetical 1-year multicentre clinical trial for either
CTD-ILD or IPF. As many widely used instruments were
found to lack full validation, an agenda for future
research is proposed.
Conclusion Identiﬁcation of consensus preliminary
domains and instruments to measure them was attained
and is a major advance anticipated to facilitate
multicentre RCTs in the ﬁeld.
BACKGROUND
The diffuse idiopathic interstitial pneumonias
describe a spectrum of parenchymal lung diseases
sharing clinical, physiological, radiological and
pathological similarities, including varying degrees
of ﬁbrosis, inﬂammation and vascular injury.1
Idiopathic pulmonary ﬁbrosis (IPF) is associated
with usual interstitial pneumonia (UIP), poor sur-
vival and limited treatment options.2 Interstitial lung
disease (ILD), most typically presenting as non-
speciﬁc interstitial pneumonitis, is a leading cause of
death in systemic sclerosis (SSc)3 and a prominent
clinical feature of other connective tissue diseases
(CTDs), including idiopathic inﬂammatory myop-
athy (IIM) and Sjögren syndrome. UIP is also found
in rheumatoid arthritis (RA) and IIM.4 5
Current evaluations of therapies focus on patient
survival or markers of chronic disease progression,
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Key messages
Why is the key question?
▸ Can a core set of outcome measures that are
reliable and feasible be identiﬁed by experts for
use in future clinical trials in connective tissue
disease associated interstitial lung disease
(CTD-ILD) and idiopathic pulmonary ﬁbrosis
(IPF)?
What is the bottom line?
▸ Using established Delphi and nominal group
techniques supplemented by patient input, a
preliminary core set of outcome measures in
CTD-ILD and IPF have been identiﬁed.
Why read on?
▸ To learn the core set of clinically meaningful
and feasible measures in CTD-ILD and IPF that
were identiﬁed and the gaps remaining.
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for example, change in forced vital capacity (FVC).6–8 Measures
of patient function, for example, 6 min walk test (6MWT), and
health-related quality of life (HRQoL) have been variably applied
with inconsistent results.6 Therapeutic research has been ham-
pered by lack of consensus on and validation of outcome measures
that reliably assess the likelihood of treatment response.
Furthermore, extra-pulmonary CTDmanifestations may confound
measures of ILD activity/severity. Patient-reported dyspnoea is
demonstrated to predict time to death, yet a satisfactory dyspnoea
instrument for ILD has not yet been identiﬁed.7 8 Clinically rele-
vant, patient-reported outcome measures (PROMs) exist for
obstructive lung disease and, in the absence of disease-speciﬁc
measures, have been utilised in trials of ILD.
The Outcome Measures in Rheumatology (OMERACT) ﬁlter9
(see online supplement) is a dynamic and iterative process/struc-
ture through which an instrument’s performance can be evalu-
ated under three criteria or points of examination: truth (face,
content, construct and criterion validity), discrimination (reliabil-
ity, sensitivity to change) and feasibility (cost, interpretability,
accessibility, safety, time). The ideal instrument satisﬁes all three
while instruments incompletely satisfying the ﬁlter may still be
immediately useful but require additional study.
The Connective Tissue Disease associated Interstitial Lung
Disease (CTD-ILD) working group of the OMERACT inter-
national consensus initiative convened to deﬁne outcome mea-
sures for use in randomised controlled trials (RCTs) in CTD-ILD.
Given the major clinical overlap, the same process was used in
parallel for IPF. We report the results of a three-component
process: medical expert Delphi exercise, patient perspective inves-
tigations and a combined medical expert and patient participant
nominal group technique (NGT) meeting leading to identiﬁcation
of preliminary core sets of domains with corresponding instru-
ments that are clinically meaningful and feasible in the context of
a 1-year multi-centre RCT for each CTD-ILD and IPF. These sets
of instruments are proposed as the minimum outcome measures
to be used in future RCTs and registries.
METHODS
Medical expert Delphi process
Delphi
International experts (n=270) were identiﬁed by authorship in
peer-reviewed journals, specialty society membership and peer
recommendations, and invited to participate in the web-based
Delphi process.10–12 This began with an ‘item-collection’ stage
called Tier 0, wherein participants nominated an unrestricted
number of potential domains (qualities to measure) and instru-
ments (speciﬁc tools for use as a measure) perceived as relevant
for inclusion in a hypothetical 1-year RCT. This exercise pro-
duced a list of >6700 items—reduced only for redundancy,
organised into 23 domains and 616 instruments and supplemen-
ted by expert advisory teams of pathologists and radiologists.
The results of Tier 0 provided the content for sequential
web-based surveys: Tiers 1, 2 and 3 which progressively
reduced the number of voting items as the items with the lowest
ratings were dismissed. Survey items for each CTD-ILD and IPF
were aligned in parallel and rated along a nine-point Likert scale
from 1 (‘not at all important’) to 9 (‘absolutely important’),
with ‘insufﬁciently familiar’ a voting alternative. An extensive
online repository of item-related journal articles was available to
participants throughout the process.
Analysis
A cut-off of <4 (median rating) was applied to ratings from the
large number of voting items in Tier 1. Cluster analyses were
applied to the ratings in Tiers 2 and 3 avoiding the use of an
arbitrary cut-off, thus allowing items to aggregate independently
providing an unbiased analysis of agreement among raters.12 A
nine-cluster analysis was initially applied and reduced to three
clusters for all items during both tiers.
Patient perspective investigation
Patient participation is recognised as integral to development of
outcome measures by OMERACT, the US Food and Drug
Administration and European Medicines Agency.9 13 To investi-
gate the patient perspective in CTD-ILD, a set of qualitative
studies were conducted: focus groups (60–90 min) of 8–12 con-
sented participants with CTD-ILD were selected by convenience
sampling and asked 1) how their life has changed since the diag-
nosis of their lung disease? and 2) how their lung disease has
changed over time? Patient perspective data in 20
English-speaking patients with IPF were previously available.14
Content was extracted from verbatim transcripts and inductive
analysis was applied to minimise investigator bias.15 Following
each focus group, CTD-ILD participants (study patients with
IPF were not available) rated on a seven-point Likert scale the
importance of the domains identiﬁed in Tier 0 of the medical
expert Delphi process.
NGT meeting
At the 2012 OMERACT 11 conference and the 2012 American
Thoracic Society (ATS) International Conference, data from the
Delphi and the patient perspective investigations were reviewed
by medical and patient experts. Following this, a face-to-face
meeting was held to apply NGT to the overall results.
At the NGT, evaluation of each domain was led by assigned
teams of medical and patient participants who presented
evidence-based reviews focusing on instrument validation in
accordance with the OMERACT ﬁlter.9 12 Several weeks prior
to team assembly, interactive educational sessions with the
patient participants examined each domain and instrument. The
teams served as a resource for evidence-based information
during the discussion phases.
After each team presentation, all participants engaged in a
‘round-robin’ discussion allowing equal speaking time per par-
ticipant10–12 over two to three rounds examining acceptance or
rejection of an item, potential clinical endpoint assignment, and
determination for new instrument development within that
domain. Each round of discussions was followed by group
voting.
All participants were requested to register a vote for each
item. With participants’ full knowledge, responses from all phy-
sicians and patients with CTD-ILD were tabulated for
CTD-ILD, with only those from pulmonologists and patients
with IPF for IPF. All votes were recorded. (The radiologist
voting was tabulated as a pulmonologist.) A priori, acceptance
was agreed upon as ≥70% afﬁrmative votes.16 Voting addressed
inclusion/exclusion of items based on the OMERACT ﬁlter and
whether the patient perspective and evidence-based data war-
ranted the need for new instrument development for that corre-
sponding domain.
RESULTS
Medical expert Delphi
A total of 254 (137 pulmonologists, 113 rheumatologists and 4
cardiologists) engaged in the Delphi process. Seventy-four per
cent reported their primary ﬁeld of interest being ILD.
Participation through all stages exceeded 97%. Six domains
identiﬁed were: Dyspnoea, HRQoL, Lung Physiology/Function,
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Lung Imaging and Survival, and Medications for each CTD-ILD
and IPF. Eighteen instruments were identiﬁed for each
CTD-ILD and IPF (tables 1–4).
Focus groups
Focus groups were conducted with patients (n=45) in IIM-ILD
(n=11), RA-ILD (n=13), SSc-ILD (n=17) and other CTD diag-
noses (n=4) (table 5). Patient participants attributed importance
to cough, dyspnoea, fatigue, participation (in family, social and
leisure activities, work within and outside the home), physical
function, self-care and sleep in the questionnaire and the focus
groups. Changes in cough were perceived as reﬂecting potential
worsening ILD. Dyspnoea largely carried descriptors different
from current instruments. Patients with IPF identiﬁed cough,
dyspnoea and HRQoL effects as central symptoms.14
OMERACT 11/ATS 2012/Domain Team meetings
Discussions and voting at the OMERACT 11/ATS 2012/Domain
Team meetings resulted in the following changes based on the
patient perspective data or strong evidence in recent literature
(detailed in online supplement):
▸ Cough was reintroduced, discussed and voted upon at the
NGT.
▸ To satisfy the reintroduction of Cough, Leicester Cough
Questionnaire (LCQ) was introduced as an interim instru-
ment to assess Cough.
▸ The Mahler Dyspnea Index (MDI) and University of
California San Diego Shortness of Breath Questionnaire
(UCSD-SBQ) were reintroduced under Dyspnoea for use in
CTD-ILD and IPF, respectively, based on substantive ﬁndings
in an updated literature review.
▸ For feasibility, HRQoL would capture ‘fatigue’, ‘participa-
tion’, ‘physical function’, ‘self-care’ and ‘sleep’ until disease-
speciﬁc investigations into these components were
conducted.
▸ NGT voting would include whether development of new
instruments for Dyspnoea, Cough and HRQoL are needed.
▸ Owing to variability of therapies, concern regarding
Medications as a core domain was expressed. However, being
identiﬁed as important in the Delphi, a statement of clariﬁca-
tion would be constructed at the NGT.
▸ ‘All-Cause Mortality’ was introduced as an assessment of
‘Survival’.
NGT results
The ﬁnal NGT panel included 10 pulmonary experts, 12
rheumatology experts and 1 radiology expert, with 5 patient
partners (tables 6–8, and see online supplement).
Table 6 displays the voting results on instruments for
CTD-ILD and IPF with striking concurrence in all domains
except for HRQoL, for which Patient Global Assessment (PtGA)
was not accepted by the pulmonary experts for IPF.
Tables 7 and 8 present the content of the NGT discussions in
the context of the OMERACT ﬁlter with items of special inter-
est highlighted below.
It was agreed that ‘Medications’ (ie, the incremental increase/
decrease of glucocorticoid and/or immunosuppressive therapy)
should be viewed as protocol speciﬁc rather than a core domain.
Depending on study design, ‘Medications’ may be either a
dichotomous interpretation of treatment efﬁcacy/failure or a
reﬂection of changes in disease activity.
The lack of validated biomarkers was fully discussed. No
items for bio-specimen evaluation emerged from the Delphi
exercise but the importance of future biomarker research was
planned for during the meeting. Consensus is required to deﬁne
the minimal standards for investigation-related bio-banking and
systematic access to samples by investigators.17
Table 3 Results of the Delphi Tier 3 cluster analysis of domains
with median/mean reported
Five domains identified for each CTD-ILD and IPF
Domain name
CTD-ILD (median/mean)
ratings on a 9-point scale
IPF (median/mean)
ratings on a 9-point
scale
Dyspnoea (8.0/7.8) (8.0/8.1)
Health-related
quality of life
(8.0/7.7) (8.0/7.8)
Lung imaging (9.0/8.3) (9.0/8.3)
Lung physiology/
function
(9.0/8.7) (9.0/8.7)
Survival (8.0/8.2) (9.0/8.4)
Medications (8.0/7.2) (7.0/7.3)
CTD-ILD, connective tissue disease associated interstitial lung disease; IPF, idiopathic
pulmonary fibrosis.
Table 1 Reduction of domains and instruments in the Delphi
process
Phase
yielded
Analysis
method
Domains
CTD-ILD/IPF
Instruments
CTD-ILD/IPF
Participant
Dropout
(%)
Tier 0 Intense
review
133
nominations
>>23
>6700
nominations
>>616/616
0
Tier 1 <4 median
cut-off
21 71/71 2
Tier 2 cluster
analysis
13 58/61 <1
Tier 3 cluster
analysis
5/5 18/18 0
CTD-ILD, connective tissue disease associated interstitial lung disease; IPF, idiopathic
pulmonary fibrosis.
Table 2 Domain results of Tier 0
Tier 0 results of 23 domains
Survival Mental health
Biomarkers Sleep
Imaging Global assessment
Lung physiology/function HRQoL
Lung parenchyma Physical function
Lung vascular Participation
Cardiac function Employment/work productivity
Composite scores Medication
Gastroesophageal reflux Extra-pulmonary CTD features
Cough Comorbidities
Dyspnoea Barriers to care
Fatigue
CTD, connective tissue disease; HRQoL, health-related quality of life.
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DISCUSSION
These comprehensive international investigations are the ﬁrst to
identify core sets of domains in each CTD-ILD and IPF along
with a provisional consensus on a minimum cadre of feasible
and clinically meaningful outcome measures/instruments. The
proposed measures are intended to be a common denominator
across future RCTs, longitudinal observational studies and
natural history registries until work can be done that substanti-
ates a truly durable framework. The rigorous consensus
methodologies of OMERACT outline the overall status of the
ﬁeld. Importantly, this is the ﬁrst study in ILD to incorporate
patient participants in panel meetings or guidelines. From the
synergy of these investigations, domains which require develop-
ment of new instruments were also identiﬁed, thus providing
guidance for imminent research.
Based on the current data, FVC (100% acceptance) was the
measure that the group favoured most for each CTD-ILD and
IPF. Again, we emphasise that the overarching construct of this
exercise was limited to that of a hypothetical RCTof 1-year dur-
ation. FVC has been shown to be a consistently reliable serial
variable in IPF. Declines in FVC correlate with increased risk of
subsequent mortality,4 7 8 18–22 although no data exist demon-
strating that improvement in FVC correlates with improved sur-
vival. Thus, utilising FVC as an endpoint requires consideration
of the clinically meaningful magnitude of change independent
of potential impact on mortality. This is particularly relevant in
studies of short duration.
While changes in FVC have been shown to be reproducible in
SSc-ILD, there are insufﬁcient RCT-derived data to evaluate this
in other forms of CTD-ILDs.3–5 20 There are confounding
issues of vasculopathy, pulmonary hypertension, cardiac involve-
ment, chest wall impairment and systemic disease activity that
are often coexistent in CTD-ILDs. Nonetheless, FVC may most
reliably and sensitively reﬂect the contribution of parenchymal
disease above other endpoints.
Though a relative change from baseline predicted is pre-
ferred to absolute change from normal values, these changes
are recognised as non-parametric in FVC. Thus a discrete
clinically relevant threshold of minimal change was not able
to be agreed upon in either IPF or CTD-ILD. Further, efforts
to validate serial variables are challenged by variations in the
rate of disease progression, with interval changes of FVC20 22
more likely to represent a true change in rapidly progressive
disease than in less progressive disease that crosses the same
threshold. Extrapolation between two value points will
provide less reliable information than continuous variables;
therefore, identiﬁcation of a minimal clinically important dif-
ference (MCID) would be misleading without accommodating
for these non-parametric changes. Panel discussions surround-
ing Diffusion Capacity of Lung for Carbon Monoxide
(DLCO) reﬂected the multiple confounders for this instru-
ment, with ranking of FVC as being the favoured marker
above DLCO. A threshold of clinically meaningful change was
not determined for DLCO.
Table 4 Results from Tier 3 of Delphi
Domain Instrument
Acceptance
in
Dyspnoea Borg Dyspnea Index CTD-ILD IPF
MRC Breathlessness (Chronic Dyspnea)
Scale or the Modified MRC Dyspnea Scale
CTD-ILD IPF
Borg Dyspnea Index pre and post exercise CTD-ILD –
HRQoL Medical Outcomes Trust Short Form 36
health survey
CTD-ILD IPF
St George’s Dyspnoea Respiratory
Questionnaire
– IPF
Visual analogue scale of Patient
Assessment of Disease Activity
CTD-ILD IPF
Ability to carry out activities of daily living CTD-ILD –
Health Assessment Questionnaire Disability
Index
CTD-ILD –
Lung imaging Extent of honeycombing on HRCT CTD-ILD IPF
Extent of reticulation on HRCT – IPF
Extent of ground glass opacities on HRCT CTD-ILD –
Overall extent of ILD on HRCT CTD-ILD IPF
Lung physiology/
function
Supplemental oxygen requirement CTD-ILD IPF
FVC on spirometry CTD-ILD IPF
Diffusion capacity of lung for carbon
monoxide
CTD-ILD IPF
6MWT with maximal desaturation on pulse
oximetry
CTD-ILD IPF
6MWT for distance – IPF
Survival Time to decline in FVC CTD-ILD IPF
Progression-free survival CTD-ILD IPF
Time to death – IPF
Medications Increase or decrease in glucocorticoids CTD-ILD IPF
Increase or decrease in concomitant
immune suppressive agents
CTD-ILD IPF
6MWT, 6 min walk test; CTD-ILD, connective tissue disease associated interstitial lung
disease; FVC, forced vital capacity; HRCT, high-resolution CT; IPF, idiopathic
pulmonary fibrosis; HRQoL, health-related quality of life; MRC, Medical Research
Council.
Table 5 Characteristics of patients with CTD-ILD participating in the focus groups
Group CTD type Location Participants Gender
Age (years)
Mean (SD) Race
1 Various Winnipeg, Manitoba, Canada 9
1 IIM, 2 RA,
4 SSc, 2 SLE
8 F, 1 M 53.6 (16.2) 8 C, 1 O
2 RA Toronto, Canada 7 7 F, 0 M 64.3 (9.0) 4 C, 2 A, 1 AC
3 SSc Baltimore, Maryland, USA 6 3 F, 3 M 58.2 (9.1) 6 C
4 IIM Baltimore, Maryland, USA 7 4 F, 3 M 52.4 (10.5) 5 C; 2 AA
5 Various New Orleans, Louisiana, USA 9
3 IIM, 4 RA,
1 SjS, 1 SLE
6 F; 3 M 53.8 (15.5) 4 C; 4 AA; 1 H
6 SSc New Orleans, Louisiana, USA 7 5 F; 2 M 54.6 (5.7) 4 AA; 3 C
A, Asian; AA, African American; AC, African Caribbean; C, Caucasian; CTD-ILD, connective tissue disease associated interstitial lung disease; F, female; H, Hispanic; IIM, idiopathic
inflammatory myopathy; M, male; O, other; RA, rheumatoid arthritis; SjS, Sjögren’s syndrome; SLE, systemic lupus erythematosus.
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Neither the 6MWT nor measures of oxygen desaturation sur-
vived the NGT process; although deemed feasible they were
considered weak in discrimination in addition to construct and
criterion validity. The need for supplemental oxygen was not
accepted; changes in oxygenation, as judged partly by oxygen
desaturation, are difﬁcult to interpret since they do not correlate
well with the sensation of dyspnoea or changes in disease pro-
gression in mild to moderate disease.19 23
The importance of patient-reported dyspnoea for assessing
prognosis and disease progression are well recognised.1 7 8 We
identiﬁed the Dyspnea 1224 and the Medical Research Council
Dyspnea Scale18 19 as the best currently available instruments in
CTD-ILD and in IPF, yet data are essentially lacking in
CTD-ILD. Though the MDI has some demonstrated validity in
SSc-ILD20, NGT panelists allocated this interviewer-
administered instrument to the research agenda for CTD-ILD,
voicing concerns of poor feasibility and uncertain reliability.
The UCSD-SBQ was accepted for use in studying IPF.21 It was
agreed that development of new Dyspnoea instruments is war-
ranted to speciﬁcally reﬂect the restrictive lung processes of
CTD-ILD and IPF.
The Short Form 36 (SF-36) was recognised as a generic
HRQoL instrument as anxiety, fatigue, participation, physical
function, self-care and sleep are important to patients.25 The St
George’s Respiratory Questionnaire, although endorsed, lacked
speciﬁcity in CTD-ILD and IPF.26 27 It was agreed that a new
disease-speciﬁc instrument should be developed.
PtGA, previously validated across rheumatic and non-
rheumatic diseases, correlates with dyspnoea in CTD-ILD28 29
and was accepted as a measure in CTD-ILD with improvements
greater than 10 mm agreed upon as an MCID. PtGA not being
validated in IPF was allocated to the research agenda in IPF.
PtGA may also serve as an ‘anchor’ to determine MCIDs for
Table 7 Relation of CTD-ILD preliminary core set instruments to aspects of OMERACT filter in CTD-ILD
CTD-ILD Dyspnoea Cough HRQoL
Lung
physiology
Lung
imaging Survival
Instruments D-12 MRC LCQ SGRQ SF-36 PtGA FVC DLCO HRCT—overall
extent of disease
All-cause
mortality
Time to decline
in FVC
Truth
Face validity Y Y Y Y Y Y Y Y Y Y Y
Content validity Y Y Y Y Y Y Y Y Y Y Y
Construct validity Y Y NT Y Y NT Y ± Y Y NT
Criterion validity NT NT NT NT NT NT No No Y Y NT
Discrimination
Discriminatory Y Y NT Y Y NT ± ± Yes, except± for GGO No Y
Reliable Y Y NT NT Y NT Y N Yes, except± for GGO Y NT
Reproducible NT NT NT NT NT NT Y ± Y N/A NT
Sensitive to change Y Y NT NT Y NT Y ± Yes but relatively slow N/A Y
Feasibility
Cost effective Y Y Y Y Y Y Y Y Y No* Y
Interpretability Y Y Y Y Y Y Y Y Y Y Y
Readily available Y Y Y Y Y Y Y Y Y Y Y
Safe for patients Y Y Y Y Y Y Y Y ± Y Y
Patient-derived content† Y No No No No N/A N/A N/A N/A N/A N/A
PtGA is adopted under HRQoL, though it is an independent instrument.
*Not cost effective as a primary efficacy endpoint but highly cost effective as a secondary endpoint to detect treatment toxicity—see text for discussion on ‘survival’
†US Food and Drug Administration advocates patient-reported instruments be developed by qualitative data supplied by patients.18 19
±, ambiguous; CTD-ILD, connective tissue disease associated interstitial lung disease; D-12, Dyspnea-12; DLCO, diffusion capacity of lung for carbon monoxide; FVC, forced vital
capacity; GGO, ground glass opacity; HRCT, high-resolution CT; LCQ, Leicester Cough Questionnaire; MRC, Medical Research Council Dyspnea Scale; N/A, not applicable; NT, not yet
tested; OMERACT, Outcome Measures in Rheumatology; PtGA, Patient Global Disease Activity; SGRQ, St George’s Respiratory Questionnaire; SF-36, Short Form 36; Y, yes.
Table 6 Results of nominal group proceedings with percentage
for acceptance (see online supplement for expanded voting tables)
Instrument
CTD-ILD
PULM+RHEUM+patients
with CTD-ILD
IPF
PULM+patient
with IPF
Dyspnoea
MRC Chronic
Dyspnea Scale
7/9+9/12+2/3=75% 10/11+1/1=92%
Dyspnea 12 8/10+11/12+3/3=88% 6/9+1/1=70%
UCSD-SBQ N/A 7/9+1/1=80%
Cough
Leicester cough
questionnaire
7/10+10/12+2/2=79% 8/10+1/1=82%
HRQoL
Short Form 36 10/10+11/11+3/3=100% 8/10+1/1=82%
SGRQ 9/10+9/11+2/2=87% 8/10+1/1=82%
VAS-PtGA 10/10+11/12+2/2=96% N/A
Lung imaging
Overall extent of ILD
on HRCT
11/11+9/11+3/3=92% 10/10+1/1=100%
Lung physiology
Forced vital capacity 10/10+11/11+3/3=100% 10/10+1/1=100%
Diffusion capacity of
lung
10/10+8/10+3/3=91% 10/10+1/1=100%
Survival
All-cause mortality Unanimous agreement Unanimous
agreement
CTD-ILD, connective tissue disease associated interstitial lung disease; HRCT,
high-resolution CT; HRQoL, health-related quality of life; IPF, idiopathic pulmonary
fibrosis; MRC, Medical Research Council; PtGA, Patient Global Assessment; PULM,
pulmonary specialist; RHEUM, rheumatology specialist; SGRQ, St George’s Respiratory
Questionnaire; UCSD-SBQ, University of California San Diego Shortness of Breath
Questionnaire; VAS, visual analogue scale.
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recently developed PROMs, such as the King’s Brief ILD Health
Assessment Questionnaire (K-BILD).30
The extent of ground-glass opacities, honeycombing and/or
reticulations on high-resolution CT (HRCT) scan each merited
careful consideration as outcome measures. However, taken sep-
arately each was felt to incompletely capture disease progression
in either CTD-ILD or IPF. The overall extent of ILD on HRCT
was accepted to provisionally describe the most appropriate and
feasible composite of radiological abnormalities to monitor for
disease progression.31 32 No speciﬁc assessment tool at this time
was able to be conﬁdently identiﬁed as it is not yet clear
whether subjective or automated objective assessment is the
more accurate approach. Though serial HRCT raises concern
for patient safety, validation studies of less radio-intense
methods of HRCT serial assessment33 are underway.
Progression-free survival in IPF was agreed to have merit,34
however the group was undecided as to the practicality of this
endpoint in the context of a trial limited to 1 year’s duration.
Mortality was minimal or absent in two recent RCTs of
SSc-ILD.35 36 There are cogent arguments for and against survival
as the primary outcome in studies of IPF.34 37 Regardless of this
unresolved debate, mortality was recognised as an essential end-
point in all treatment trials as it provides a harm signal,34 37 with
all-cause mortality identiﬁed as a valid measure of survival in
CTD-ILD and IPF. The utility of other measures of progression-
free survival in RCTs requires further investigation of candidate
instruments before recommending their use in RCTs.
While the domain of Cough did not survive the Delphi
process, it was important to patient participants. Additionally,
there is a correlation between cough and IPF progression38 and
with ILD severity in SSc.39 In SSc-ILD, cough adversely
impacted HRQoL and improved with treatment.39 The LCQ
was selected as an interim measure as it was deemed more able
to capture frequency, quality and intensity, and impact on
HRQoL. It was also most feasible to administer.40 41
Primary and secondary endpoint status of the proposed mea-
sures were considered, intensely discussed and even voted upon
during the NGT. However, at this preliminary stage and given
the lack of full validation of the core measures, the consensus
was to pursue further data. A more careful approach to end-
point status declarations entails ad hoc and prospective perform-
ance analyses of these measures.
Though we recommend these proposed measures for all
future research ventures, continued use of measures outside this
core set, for clinical practice and research purposes, is fully
expected with further research into their performance antici-
pated and necessary. Rather, this endeavour deﬁnes the currently
available, best validated and feasible instruments while providing
a much needed prioritised research agenda focus to the research
community.
This project applied rigorous multi-investigational processes
that captured the perspectives of the international ILD expert
community and the life experience of patients with ILD to iden-
tify a set of domains and measures. Participation remained
robust through all tiers of the consensus process.
The importance of patient participation is supported by the
incorporation of HRQoL, Participation and Fatigue in the RA
core set for RCTs. From a practical perspective, qualitative data
collection involved only English-speaking patients from North
America, and results may be affected by cultural, environmental
and resource-related effects requiring further investigations to
follow up our reported ﬁndings. Nevertheless, the engagement
of patients as partners in the iterative process was important in
identifying and re-capturing areas of potentially meaningful
measures of disease activity.
CONCLUSIONS
It is critical that valid and clinically useful instruments be devel-
oped and validated to assess the likelihood of treatment
response in these disorders. Identiﬁcation of consensus
Table 8 Relation of IPF preliminary core set instruments to aspects of OMERACT filter in IPF
IPF Dyspnoea Cough HRQoL
Lung
physiology
Lung
imaging Survival
Instruments D-12 MRC UCSD-SBQ LCQ SGRQ SF-36 FVC DLCO
HRCT—overall
extent of disease
All-cause
mortality
Truth
Face validity Y Y Y Y Y Y Y Y Y Y
Content validity Y Y Y Y Y Y Y Y Y Y
Construct validity Y Y Y NT Y Y Y Y Y Y
Criterion validity NT NT NT NT NT NT No No Y Y
Discrimination
Discriminatory NT NT Y NT NT NT ± ± Y No
Reliable NT NT NT NT Y Y Y N Y Y
Reproducible NT NT NT NT Y NT Y ± Y N/A
Sensitive to change NT NT Y NT Y Y Y Y Yes but relatively slow N/A
Feasibility
Cost effective Y Y Y Y Y Y Y Y Y No*
Interpretability Y Y Y Y Y Y Y Y Y Y
Readily available Y Y Y Y Y Y Y Y Y Y
Safe for patients Y Y Y Y Y Y Y Y ± Y
Patient-derived content† Y No No No No No N/A N/A N/A N/A
*Not cost effective as a primary efficacy endpoint but highly cost effective as a secondary endpoint to detect treatment toxicity—see text for discussion on ‘survival’.
†US Food and Drug Administration advocates patient-reported instruments be developed by qualitative data supplied by patients.18 19
±, ambiguous; D-12, Dyspnea-12; DLCO, diffusion capacity of lung for carbon monoxide; FVC, forced vital capacity; HRCT, high-resolution CT; IPF, idiopathic pulmonary fibrosis; LCQ,
Leicester Cough Questionnaire; MRC, Medical Research Council Dyspnea Scale; N/A, not applicable; NT, not yet tested; OMERACT, Outcome Measures in Rheumatology; SGRQ, St
George’s Respiratory Questionnaire; SF-36, Short Form 36; UCSD, University of San Diego Shortness of Breath Questionnaire; Y, yes.
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preliminary domains and instruments to measure them was
attained and is a major advance anticipated to facilitate multi-
centre RCTs in the ﬁeld. However, none of the provisional end-
points were ultimately felt to be either ideal or fully validated.
Feasible endpoints like FVC are not perfect; more rigorous end-
points like mortality, particularly in the setting of CTD-ILD,
lack feasibility. Thus, selecting the best non-ideal endpoints
from a larger group of non-ideal endpoints still leaves us with
much work which includes further validation of existing and
development of new instruments.
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